SCHEMBL15059195

SCHEMBL15059195

CCOC(=O)c1cnc(N)cc1Nc1cccc(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 5/20 0.50
▸ AURKA O14965 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ CDC25B P30305 2/20 0.47
▸ KDR P35968 1/20 0.47
▸ SYK P43405 2/20 0.47
▸ TP53 P04637 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ SIRT5 Q9NXA8 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ AKR1C3 P42330 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15058850 0.86 AURKB (0.48) AURKBAURKASMN1; SMN2ALDH1A1MAPT
SCHEMBL15059636 0.82 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1LMNAHPGDL3MBTL1
SCHEMBL15058707 0.81 PIK3CA (0.56) —
SCHEMBL16201838 0.79 EGFR (0.51) SMN1; SMN2NPC1RAB9A
SCHEMBL17134535 0.78 AURKB (0.55) AURKBAURKASMN1; SMN2ALDH1A1MAPT
SCHEMBL15059077 0.77 RAB9A (0.51) SMN1; SMN2ALDH1A1LMNAHPGDMAPT
SCHEMBL17134742 0.76 AURKB (0.56) AURKBAURKASMN1; SMN2ALDH1A1MAPT
SCHEMBL17135080 0.76 AURKB (0.62) AURKBAURKASMN1; SMN2ALDH1A1MAPT
SCHEMBL2386230 0.76 SYK (0.59) AURKBSMN1; SMN2MAPTL3MBTL1SYK
SCHEMBL502084 0.75 ATM (0.51) SMN1; SMN2ALDH1A1LMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794569-B1 HETEROCYCLIC UREA COMPOUNDS BIOTA EUROPE LTD (GB) 2017-05-10 — — EP disclosed
EP-2794569-B1 HETEROCYCLIC UREA COMPOUNDS BIOTA EUROPE LTD (GB) 2017-05-10 — — EP disclosed
US-9060515-B2 Heterocyclic urea compounds BIOTA EUROPE LTD. (GB) 2015-06-23 — — US disclosed
US-9060515-B2 Heterocyclic urea compounds BIOTA EUROPE LTD. (GB) 2015-06-23 — — US disclosed
US-20140323486-A1 HETEROCYCLIC UREA COMPOUNDS SPERO GYRASE, INC. 2014-10-30 — — US disclosed
US-20140323486-A1 HETEROCYCLIC UREA COMPOUNDS SPERO GYRASE, INC. 2014-10-30 — — US disclosed
EP-2794569-A1 HETEROCYCLIC UREA COMPOUNDS Biota Europe Ltd (GB) 2014-10-29 — — EP disclosed
WO-2013091011-A1 HETEROCYCLIC UREA COMPOUNDS BIOTA EUROPE LTD (GB) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323486-A1 HETEROCYCLIC UREA COMPOUNDS UMPS, URB2, UROD AURKB 1952/4885AURKA 1938/4885SMN1; SMN2 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback